Literature DB >> 6194272

The behavioral effect of salbutamol (a beta-adrenergic receptor stimulant) on reserpine- and propranolol-treated rats.

Y Vardi, I Regev, M Rosenbaum, S Flechter.   

Abstract

Reserpine- and propranolol-treated rats were given salbutamol, a beta-adrenergic stimulant, intra-peritoneally in an open control study. The results suggest that salbutamol has a therapeutic effect on the depressive behavior of reserpine- and propranolol-treated rats.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6194272     DOI： 10.1007/bf00313596

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  7 in total

1.  Cellular localization of brain monoamines.

Authors:  A CARLSSON; B FALCK; N A HILLARP
Journal:  Acta Physiol Scand Suppl       Date:  1962

2.  Experimental and clinical evidence of the antidepressant effect of a beta-adrenergic stimulant.

Authors:  P Simon; Y Lecrubier; R Jouvent; A J Puech; J F Allilaire; D Widlöcher
Journal:  Psychol Med       Date:  1978-05       Impact factor: 7.723

3.  Histochemical labeling of beta-adrenergic receptors in the mouse central nervous system by 9-amino-acridin propranolol.

Authors:  E Melamed; M Luhar; D Atlas
Journal:  Neurology       Date:  1978-08       Impact factor: 9.910

4.  [Study of a beta-adrenergic stimulant and its antidepressant activity in man].

Authors:  R Jouvent; Y Lecrubier; A J Puech; H F Simon; D Widlocher
Journal:  Encephale       Date:  1977       Impact factor: 1.291

5.  Stereotaxic mapping of the monoamine pathways in the rat brain.

Authors:  U Ungerstedt
Journal:  Acta Physiol Scand Suppl       Date:  1971

Review 6.  Antidepressants, catecholamines and 5-hydroxyindoles. Trends towards a more specific research in the field of antidepressants.

Authors:  H M Van Praag
Journal:  Psychiatr Neurol Neurochir       Date:  1967 May-Jun

Review 7.  The catecholamine hypothesis of affective disorders: a review of supporting evidence.

Authors:  J J Schildkraut
Journal:  Am J Psychiatry       Date:  1965-11       Impact factor: 18.112
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.